Company intelligence / Profile preview
Tenpoint Therapeutics
Seattle, Washington, United Statestenpointtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Tenpoint Therapeutics (formerly Visus Therapeutics) has completed Phase 3 pivotal trials for BRIMOCHOL PF, a presbyopia treatment. The company has submitted a New Drug Application to the FDA and plans commercialization in the US by 2026[3][6].
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculesalpha-crystallin aggregation inhibitors
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Tenpoint Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenpoint Therapeutics.